83. アジソン病 Addison disease Clinical trials / Disease details
臨床試験数 : 20 / 薬物数 : 39 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 18
Showing 1 to 10 of 20 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05350020 (ClinicalTrials.gov) | March 14, 2022 | 29/3/2022 | The Effects of Two Brands of Hydrocortisone Injected Intramuscularly Into Deltoid and Thigh Muscles | An Open Label Pilot Study to Investigate the Effects of Two Preparations of Hydrocortisone (Hydrocortisone 100mg/ml and Solu-Cortef) Injected Intramuscularly Into the Deltoid and Upper Thigh Muscle During the State of Hypocortisolaemia An Open Label Pilot Study to Investigate the Effects of Two Preparations of Hydrocortisone (Hydrocor ... | Addison's Disease | Drug: Solu-Cortef 100 MG Injection;Drug: Hydrocortisone 100mg/ml | The London Clinic | NULL | Recruiting | 18 Years | 70 Years | All | 8 | Phase 4 | United Kingdom |
2 | NCT03210545 (ClinicalTrials.gov) | March 2, 2021 | 29/6/2017 | A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) | A Dose-response Study of Markers of Glucocorticoid Effects (DOSCORT): A Double-blinded, Randomized, 2-dose, Cross-over Study A Dose-response Study of Markers of Glucocorticoid Effects (DOSCORT): A Double-blinded, Randomized, ... | Addison Disease | Drug: Betamethasone | Göteborg University | NULL | Recruiting | 20 Years | 65 Years | All | 30 | Phase 4 | Sweden |
3 | EUCTR2015-001090-40-GB (EUCTR) | 22/06/2015 | 08/04/2015 | The effects of two brands of hydrocortisone injected intramuscularly into deltoid and thigh muscles | An open label pilot study to investigate the effects of two preparations of hydrocortisone (Hydrocortisone 100mg/ml and Solu-Cortef) injected intramuscularly into the deltoid and upper thigh muscle during the state of hypocortisolaemia - Effects of 100mg Hydrocortisone injection into Deltoid & Thigh An open label pilot study to investigate the effects of two preparations of hydrocortisone (Hydrocor ... | Addison's Disease MedDRA version: 20.1;Level: PT;Classification code 10001130;Term: Addison's disease;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Addison's Disease MedDRA version: 20.1;Level: PT;Classification code 10001130;Term: Addison's diseas ... | Trade Name: Solu-Cortef Product Name: Solu-Cortef INN or Proposed INN: Hydrocortisone Trade Name: Hydrocortisone 100mg/ml Product Name: Hydrocortisone 100mg/ml INN or Proposed INN: Hydrocortisone Trade Name: Solu-Cortef Product Name: Solu-Cortef INN or Proposed INN: Hydrocortisone Trade Name: Hydro ... | The London Clinic | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 8 | Phase 4 | United Kingdom | ||
4 | EUCTR2012-001104-37-GB (EUCTR) | 06/10/2014 | 24/07/2014 | pulses study | Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia - the pulses study Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary t ... | Addison's disease and Congenital Adrenal Hyperplasia MedDRA version: 17.0;Level: LLT;Classification code 10011195;Term: Cortisol;System Organ Class: 100000004848 MedDRA version: 17.0;Classification code 10020518;Term: Hydrocortisone;System Organ Class: 100000004848;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Addison's diseaseand Congenital Adrenal Hyperplasia MedDRA version: 17.0;Level: LLT;Classification c ... | Trade Name: hydrocortisone sodium phosphate Product Name: hydrocortisone sodium phosphate INN or Proposed INN: hydrocortisone sodium phosphate Trade Name: hydrocortisone Product Name: hydrocortisone INN or Proposed INN: hydrocortisone Trade Name: hydrocortisonesodium phosphate Product Name: hydrocortisonesodium phosphate INN or Propose ... | University Hospitals Bristol NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom | ||||
5 | NCT02096510 (ClinicalTrials.gov) | August 2014 | 28/11/2013 | Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia | Addison Disease;Adrenal Hyperplasia Congenital | Drug: Solu-Cortef;Drug: Cortef | Haukeland University Hospital | NULL | Recruiting | 18 Years | 65 Years | Both | 10 | Phase 1/Phase 2 | Norway |
6 | NCT02152553 (ClinicalTrials.gov) | May 2014 | 12/5/2014 | Biomarker(s) for Glucocorticoids | Protein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Adrenal Insufficiency Protein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Ad ... | Addison Disease | Drug: Hydrocortisone;Drug: Placebo | Vastra Gotaland Region | NULL | Completed | 20 Years | 60 Years | All | 11 | N/A | Sweden |
7 | EUCTR2013-004189-33-NO (EUCTR) | 28/11/2013 | 30/10/2013 | A trial comparing continuous subcutaneous hydrocortisone therapy with pulsatile subcutaneous hydrocortisone therapy in patients with Addison`s disease A trial comparing continuous subcutaneous hydrocortisone therapy with pulsatile subcutaneous hydroco ... | ULTRADIAN SUBCUTANEOUS HYDROCORTISONE (USHI) INFUSION IN ADDISON’S DISEASE | Addison`s disease;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Solu-Cortef Trade Name: Cortef 5 mg | Haukeland University Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Norway | |||
8 | NCT01847690 (ClinicalTrials.gov) | June 2013 | 23/4/2013 | Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure | Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal | Addison Disease | Drug: Hydrocortisone | Haukeland University Hospital | NULL | Active, not recruiting | 18 Years | 70 Years | Female | 20 | Phase 2 | Norway |
9 | EUCTR2012-001682-33-GB (EUCTR) | 06/09/2012 | 15/06/2012 | Rescue of Addison’s disease 2 | Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease - Rescue of Addison’s disease 2 (RADS2) Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Dise ... | Autoimmune Addison's disease: autoimmune primary adrenal insufficiency MedDRA version: 16.1;Level: PT;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 16.1;Level: LLT;Classification code 10001335;Term: Adrenal cortex insufficiency;Classification code 10001342;Term: Adrenal cortical hypofunction;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Autoimmune Addison's disease: autoimmune primary adrenal insufficiency MedDRA version: 16.1;Level: P ... | Trade Name: Mabthera infusion Product Name: Mabthera Infusion Product Code: Rituximab Trade Name: Solu-Medrone Product Name: Solu-Medrone Product Code: Methylprednisolone Trade Name: Synacthen Depot Product Name: Synacthen Depot Product Code: Tetracosactide acetate Trade Name: Mabtherainfusion Product Name: MabtheraInfusion Product Code: Rituximab Trade Name: Solu-Me ... | Newcastle upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ... | United Kingdom | ||
10 | EUCTR2011-002687-25-DE (EUCTR) | 16/11/2011 | 06/10/2011 | Evaluation of the time to cortisol levels required in critical illness (>1000 nmol/l) and safety of hydrocortisone, after subcutaneous injection in patients with chronic primary adrenal insufficiency(Comparison s.c. vs. i.m.) Evaluation of the time to cortisol levels required in critical illness (>1000 nmol/l) and safety of ... | Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency(PHYSCA-Trial) - PHYSCA- Trial Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Inj ... | Adrenal insufficiency under chronic glucocorticoid replacement MedDRA version: 14.0;Level: PT;Classification code 10001130;Term: Addison's disease;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.0;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Adrenal insufficiency under chronic glucocorticoid replacement MedDRA version: 14.0;Level: PT;Classi ... | Trade Name: Hydrocortison 100 mg (Pfizer®) in 2 ml solvent INN or Proposed INN: Hydrocortisone Other descriptive name: HYDROCORTISONE HYDROGEN SUCCINATE Trade Name: Hydrocortison 100 mg (Pfizer®) in 2 ml solvent INN or Proposed INN: Hydrocortisone Other d ... | University Hospital of Wuerzburg | NULL | Not Recruiting | Female: yes Male: yes | 12 | Germany |